FloraWorks News Releases

FloraWorks Announces TruCBN(TM) Readiness for the CMS Substance Access BEI Program with Full Clinical and Safety Substantiation

Thu, 09 Apr 2026 08:00:00 -0400

TruCBN(TM) demonstrated statistically significant improvement in sleep quality in a published RCT and is supported by a full GLP safety package Portland, Oregon--(Newsfile Corp. - April 9, 2026) - FloraWorks today announced that TruCBN™ 50 mg softgels are available to healthcare organizations evaluating sleep-focused hemp products for the CMS Substance Access Beneficiary Engagement Incentive (BEI) program.In a published 1,020-person randomized, double-blind, placebo-controlled clinical trial,...

CORRECTION FROM THE SOURCE: FloraWorks Highlights New Study Showing CBN Reverses Cognitive Decline in Aging Mice

Mon, 28 Jul 2025 12:15:00 -0400

Peer-reviewed research published in Redox Biology supports the therapeutic potential of Cannabinol (CBN) in brain aging and metabolic health. Correction from Source: This press release corrects and replaces the version issued by FloraWorks on July 7, 2025, titled "Salk Institute Study Shows FloraWorks CBN Reverses Age-Related Cognitive Decline".Portland, Oregon--(Newsfile Corp. - July 28, 2025) - FloraWorks, a developer of high-purity rare cannabinoid ingredients, is drawing attention to new...

Salk Institute Study Shows FloraWorks' CBN Reverses Age-Related Cognitive Decline

Mon, 07 Jul 2025 08:00:00 -0400

Breakthrough findings highlight TruCBN(TM) as a potential therapeutic for brain aging and cognitive health. Portland, Oregon--(Newsfile Corp. - July 7, 2025) - In a groundbreaking study published in Redox Biology, researchers at the Salk Institute for Biological Studies have demonstrated that Cannabinol (CBN)-specifically FloraWorks' high-purity TruCBN™-can prevent and/or reverse cognitive decline in a preclinical model of accelerated aging. The findings position CBN as a leading candidate in...

FloraWorks Announces Peer-Reviewed Publication of Groundbreaking Sleep Study on TruCBN(TM)

Wed, 31 Jul 2024 09:00:00 -0400

TruCBN(TM) is the first cannabinoid proven to be a safe and effective sleep aid in the largest blinded, randomized, placebo-controlled clinical trial ever conducted on a single cannabinoid. Portland, Oregon--(Newsfile Corp. - July 31, 2024) - FloraWorks, a leader in cannabinoid therapeutic development, is proud to announce the peer-reviewed publication of its groundbreaking study on TruCBN™ in the journal Pharmaceuticals. This landmark research represents the first clinically validated sleep...

FloraWorks Appoints Dr. Matthew Roberts as Chief Operating Officer to Drive Next Phase of Growth

Mon, 08 Jul 2024 08:00:00 -0400

Portland, Oregon--(Newsfile Corp. - July 8, 2024) - FloraWorks, a leading innovator in the development and commercialization of cannabinoid therapeutics, is pleased to announce the appointment of Dr. Matthew Roberts as Chief Operating Officer (COO). With an extensive background in operational leadership, strategic development, and scientific innovation, Dr. Roberts will play a pivotal role in guiding FloraWorks through its next phase of growth and expansion.Dr. Roberts brings over 25 years of...

Clinical Validation Data for FloraWorks' TruCBN to be Presented at SLEEP 2024

Thu, 30 May 2024 11:00:00 -0400

TruCBN is the first and only cannabinoid clinically validated in a double-blind placebo-controlled trial to improve sleep quality Portland, Oregon--(Newsfile Corp. - May 30, 2024) - FloraWorks, a lead discovery and validation company advancing research of rare and novel cannabinoids for a new generation of safe and effective therapeutic solutions, announced that an abstract featuring data from a clinical study evaluating TruCBN™ has been accepted as a poster presentation at SLEEP 2024, the 38th...

Cannabinoid Biotech Leader FloraWorks to Present at Seed Showcase 2024 During J.P. Morgan Healthcare Conference

Thu, 04 Jan 2024 09:00:00 -0500

CEO Alleh Lindquist to Present the Company's Breakthrough Cannabinoid Research Approach For a New Generation of Therapeutics Portland, Oregon--(Newsfile Corp. - January 4, 2024) - FloraWorks Holdings Inc., a leading cannabinoid therapeutics company, announced it will present at Seed Showcase, part of Biotech Showcase 2024, during this year's annual J.P. Morgan Healthcare Conference in San Francisco, CA. Attendees can view FloraWorks' presentation live during the in-person event on Tuesday,...

Healthcare Industry Veteran Donald M. Casey Jr. Joins Board of Directors at Cannabinoid Biotech Leader FloraWorks

Thu, 04 Jan 2024 09:00:00 -0500

Portland, Oregon--(Newsfile Corp. - January 4, 2024) - FloraWorks Holdings Inc., a leading cannabinoid biotech company, announced the appointment of Donald M. Casey Jr. as Board Director. Casey brings over 30 years of global healthcare experience to the FloraWorks board, with an outstanding track record of identifying and commercializing medical innovations.Casey has held numerous executive leadership and board tenures, starting with 24 years at Johnson & Johnson where he rose through the ranks...

FloraWorks Appoints Cannabis Scientist Dr. Mike McCormick as VP of Strategy

Wed, 04 Oct 2023 09:00:00 -0400

Portland, Oregon--(Newsfile Corp. - October 4, 2023) - FloraWorks Holdings Inc., a leading cannabinoid therapeutics company, announced the appointment of Dr. Mike McCormick as VP of Strategy. A science and intellectual property consultant for FloraWorks since 2022, Dr. McCormick brings extensive expertise in cannabinoid biochemistry, innovation, and IP protection.Within the cannabis industry, Dr. McCormick focuses on industrial and academic technology transfer, and the development of...

FloraWorks Announces Updated Analysis of Landmark Clinical Trial; CBN Shown Effective for Sleep

Mon, 18 Sep 2023 09:00:00 -0400

Radicle Science found TruCBN(TM) to significantly improve sleep outcomes in first-ever placebo-controlled trial of pure CBN Portland, Oregon--(Newsfile Corp. - September 18, 2023) - FloraWorks Holdings Inc., a leading cannabinoid therapeutics company, announced that its flagship product TruCBN™ (a pure form of cannabinol or "CBN") demonstrated effectiveness in treating sleep disturbances in a recent landmark clinical trial independently conducted by Radicle Science. In the industry-first,...